Arbutus Biopharma (ABUS) Wins FDA Fast Track for Imdusiran
Summary
On April 14, 2026, Arbutus Biopharma Corporation (NASDAQ:ABUS) announced that the FDA granted Fast Track designation to imdusiran for the treatment of chronic h...
Description
On April 14, 2026, Arbutus Biopharma Corporation (NASDAQ:ABUS) announced that the FDA granted Fast Track designation to imdusiran for the treatment of chronic h...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source